Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effectiveness of these therapies. This study used inverse probability of treatment weighting to indirectly compare treatment outcomes of epcoritamab from the EPCORE NHL-1 trial with individual patient data from clinical practice cohorts treated with chemoimmunotherapy (CIT) and novel therapies (polatuzumab-based regimens, tafasitamab-based regimens, and chimeric antigen receptor T-cell [CAR T] therapies) for third-line or later R/R large B-cell lymphoma (LBCL) and DLBCL. In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.

中文翻译：

---

epcoritamab 与化学免疫疗法、基于 polatuzumab 的方案、基于 tafasitamab 的方案或嵌合抗原受体 T 细胞疗法在三线或后续复发/难治性大 B 细胞淋巴瘤中的治疗结果比较


许多疗法可用于治疗 ≥ 2 线治疗后的复发/难治性 （R/R） 弥漫性大 B 细胞淋巴瘤 （DLBCL），尽管关于这些疗法的比较有效性的证据很少。本研究使用治疗加权的逆概率间接比较 EPCORE NHL-1 试验中 epcoritamab 的治疗结果与接受化学免疫疗法 （CIT） 和新疗法（基于 polatuzumab 的方案、基于 tafasitamab 的方案和嵌合抗原受体 T 细胞 [CAR T] 疗法）治疗的临床实践队列的个体患者数据用于三线或晚期 R/R 大 B 细胞淋巴瘤 （LBCL） 和 DLBCL。在该分析中，epcoritamab 的反应率和总生存率显著优于 CIT 、基于 polatuzumab 的方案和基于 tafasitamab 的方案。在 R/R LBCL 中，与 CAR T 相比，epcoritamab 的反应率或生存率没有统计学意义差异。